D&D Pharmatech partner 2phase initiation · Hyundai Engineering 3participation in a trillion-won project among successive disclosures (7~8days)
D&D Pharmatech's technology-transfer partner has 7begun a clinical trial of an FAP-targeted contrast agent on 2the phase. During the same period, SD Biosensor, Cheongdam Global, Digital Daesung and Hyundai Engineering announced their respective plans to target public procurement with diagnostic products, expand their brands, strengthen their business foundations and participate in a Korea-U.S. joint-venture plant.
Get free 디앤디파마텍 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
D&D Pharmatech's global technology-transfer partner 7on announced the initiation of a clinical trial of an FAP (fibroblast activation protein)-targeted contrast agent's 2phase, the company said. The partner officially disclosed the initiation of the clinical trial.
D&D Pharmatech also separately disclosed on the same day that the 2phase initiation of a candidate FAP-targeted contrast agent had occurred. The company reported on the progress of the clinical stage.
SD Biosensor said it would target the global public procurement market with a tuberculosis diagnostic product on 8. The company announced that it would expand the product through public procurement tenders and supply channels.
Cheongdam Global 8announced that it would expand the brands participating in global pop-up events and trade fair projects. The company said it would increase participation in overseas pop-up events and trade fairs to broaden brand participation.
Digital Daesung 7announced that it would strengthen the growth foundation of its reading education brand, Hanwoori. It said that specific implementation plans would be provided through the company's disclosure.
Hyundai Engineering 8announced that it would participate in a joint Korea-U.S. lithium and boron plant project. The company introduced the project as being worth 3trillion won.
These disclosures were 7and 8announced around the same period. Each company informed investors of the announcement timing and contents in a separate disclosure.